€4 million Boehringer milestone seals positive week for deflated Evotec
This article was originally published in Scrip
Executive Summary
Evotec and Boehringer Ingelheim have identified and selected a compound to be advanced into pre-clinical development within an oncology program under their research alliance, triggering a €4 million milestone payment for Evotec.